EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy

Xuejiao Cui, Futao Wang, Cong Liu

Frontiers in Immunology · 19.01.2023 · 14

DOI: 10.3389/fimmu.2023.1062045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 19.01.2023. Verfasst von Xuejiao Cui und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Graves Ophthalmopathy. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graves’ orbitopathy (GO) is an organ-specific autoimmune disease, but its pathogenesis remains unclear. There are few review articles on GO research from the perspective of target cells and target antigens. A systematic search of PubMed was performed, focusing mainly on studies published after 2015 that involve the role of target cells, orbital fibroblasts (OFs) and orbital adipocytes (OAs), target antigens, thyrotropin receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R), and their corresponding antibodies, TSHR antibodies (TRAbs) and IGF-1R antibodies (IGF-1R Abs), in GO pathogenesis and the potentially effective therapies that target TSHR and IGF-1R. Based on the results, OFs may be derived from bone marrow-derived CD34+ fibrocytes. In addition to CD34+ OFs, CD34- OFs are important in the pathogenesis of GO and may be involved in hyaluronan formation. CD34- OFs expressing Slit2 suppress the phenotype of CD34+ OFs. β-arrestin 1 can be involved in TSHR/IGF-1R crosstalk as a scaffold. Research on TRAbs has gradually shifted to TSAbs, TBAbs and the titre of TRAbs. However, the existence and role of IGF-1R Abs are still unknown and deserve further study. Basic and clinical trials of TSHR-inhibiting therapies are increasing, and TSHR is an expected therapeutic target. Teprotumumab has become the latest second-line treatment for GO. This review aims to effectively describe the pathogenesis of GO from the perspective of target cells and target antigens and provide ideas for its fundamental treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyHumansReceptors, ThyrotropinSignal TransductionReceptors, G-Protein-CoupledPhenotype

Stichwörter der Autor:innen

Graves’ orbitopathyinsulin-like growth factor-1 receptororbital adipocytesorbital fibroblaststhyrotropin receptor

Substanzen

Receptors, ThyrotropinReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Endocrinology, Changchun Central Hospital, Changchun, China.

Zitieren

APA

Cui, X., Wang, F., & Liu, C. (2023). A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1062045

Vancouver

Cui X, Wang F, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1062045

BibTeX
@article{Cui2023,
  author = {Cui, Xuejiao and Wang, Futao and Liu, Cong},
  title = {A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy},
  journal = {Frontiers in Immunology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fimmu.2023.1062045}
}
Kostenlos starten →